Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Mircera on delaying dialysis in anemic stage 5 CKD patients not on dialysis
TCTR20190718006Phase 4Recruiting
- Sponsor
- Division of Nephrology, Chulalongkorn University
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of Epoetin alfa RB in chronic kidney disease (CKD), anaemia, sponsored by Division of Nephrology, Chulalongkorn University. Started Mar 2019; status: recruiting.
02
Drugs
Epoetin alfa RB
03
Conditions
chronic kidney disease (CKD)anaemia
Beyond the preview
Go deeper on TCTR20190718006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20190718006.